News Releases

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

January 25, 2022

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

January 24, 2022

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference

December 16, 2021

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant

December 7, 2021

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study

October 26, 2021

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

October 6, 2021

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

October 1, 2021

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium

September 14, 2021

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

September 7, 2021

Latest News & Events

Mar 10, 2025

Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties

Read More...

Mar 3, 2025

Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th

Read More...

Feb 26, 2025

Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Read More...